Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Gendre

Showing results (201-210 of 206) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 206 results.
Gastroenterologie Clinique Et Biologique|February 15, 2002
[Infliximab therapy for Crohn's disease anoperineal lesions]A Ouraghi, S Nieuviarts, J L Mougenel, et al.
Gastroenterology|March 1, 1996
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires DigestivesR Modigliani, J F Colombel, J L Dupas, et al.
Gut|February 24, 2006
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseW Reinisch, D W Hommes, G Van Assche, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 19, 2005
[Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma]L Moureau-Zabotto, E Touboul, D Lerouge, et al.
European Journal of Gastroenterology & Hepatology|March 1, 1996
Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)C Florent, A Cortot, P Quandale, et al.
International Journal of Colorectal Disease|April 25, 2001
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003S Schreiber, M Campieri, J F Colombel, et al.
Pageof 21

Showing results (201-210 of 206) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 206 results.
Gastroenterologie Clinique Et Biologique|February 15, 2002
[Infliximab therapy for Crohn's disease anoperineal lesions]A Ouraghi, S Nieuviarts, J L Mougenel, et al.
Gastroenterology|March 1, 1996
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires DigestivesR Modigliani, J F Colombel, J L Dupas, et al.
Gut|February 24, 2006
A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's diseaseW Reinisch, D W Hommes, G Van Assche, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 19, 2005
[Impact of computed tomography (CT) and 18F-deoxyglucose positron emission tomography (FDG-PET) image fusion for conformal radiotherapy in esophageal carcinoma]L Moureau-Zabotto, E Touboul, D Lerouge, et al.
European Journal of Gastroenterology & Hepatology|March 1, 1996
Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)C Florent, A Cortot, P Quandale, et al.
International Journal of Colorectal Disease|April 25, 2001
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003S Schreiber, M Campieri, J F Colombel, et al.
Pageof 21